Menu
Search
|

Menu

Close
X

Ultragenyx Pharmaceutical Inc RARE.OQ (NASDAQ Stock Exchange Global Select Market)

46.31 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 46.31
Open --
Volume --
3m Avg Volume 216,365
Today’s High --
Today’s Low --
52 Week High 91.17
52 Week Low 41.68
Shares Outstanding (mil) 42.46
Market Capitalization (mil) 2,305.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
3
FY16
0
FY15
0
EPS (USD)
FY17
-7.113
FY16
-6.201
FY15
-3.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
19,878.61
5.77
Price to Book (MRQ)
vs sector
5.37
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-62.70
14.43
Return on Equity (TTM)
vs sector
-63.52
16.13

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Emil Kakkis
President, Chief Executive Officer, Director, Since
Salary: $567,200.00
Bonus: --
Shalini Sharp
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $441,000.00
Bonus: --
Sunil Agarwal
President - Research and Development, Since 2017
Salary: $150,180.00
Bonus: $100,000.00
Karah Parschauer
Executive Vice President, General Counsel, Since 2016
Salary: $175,000.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Leveroni Ct
NOVATO   CA   94949-5746

Phone: +1415.4838800

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

SPONSORED STORIES